http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Akihiko Ueda,Hidemichi Watari,Masaki Mandai,Shunichi Fukuhara,Yasuo Sugitani,Kiyoko Ogino,Shuichi Kamijima,Takayuki Enomoto 대한부인종양학회 2022 Journal of Gynecologic Oncology Vol.33 No.6
Objective: To assess the incidence of bevacizumab-associated gastrointestinal (GI) perforation during first-line treatment of patients with ovarian, fallopian tube, or peritoneal cancer receiving neoadjuvant chemotherapy (NAC) in Japanese real-world clinical practice. Methods: A retrospective study was conducted using a healthcare claims database owned by Medical Data Vision Co., Ltd. (study period, 2008–2020). Patients who initiated first-line treatment of ovarian, fallopian tube, or peritoneal cancer were identified and divided into NAC and primary debulking surgery (PDS) groups. The incidence of bevacizumab-associated GI perforation was compared within the NAC group and between the groups. Results: Paclitaxel + carboplatin (TC) was most commonly used as first-line treatment (39.5% and 59.6% in the NAC and PDS groups, respectively). TC + bevacizumab was used in 9.3% and 11.6% of patients in the NAC and PDS groups, respectively. In the NAC group receiving TC, the proportion of patients with risk factors for GI perforation was lower among patients with versus without concomitant bevacizumab. The incidence of GI perforation in the NAC group was 0.38% (1/266 patients) in patients receiving TC + bevacizumab and 0.18% (2/1,131 patients) in patients receiving TC without bevacizumab (risk ratio=2.13; 95% confidence interval [CI]=0.19 to 23.36; risk difference=0.20; 95% CI=−0.58 to 0.97). None of the 319 patients in the PDS group receiving TC + bevacizumab had GI perforation.
Genomic Profiling Shows Increased Glucose Metabolism in Luminal B Breast Cancer
Shigeto Ueda,Hideki Takeuchi,Takashi Shigekawa,Kazuo Matsuura,Noriko Nakamiya,Hiroshi Sano,Hiroko Shimada,Eiko Hirokawa,Akihiko Osaki,Toshiaki Saeki 한국유방암학회 2013 Journal of breast cancer Vol.16 No.3
We had previously reported a close association between pathological response and the maximum tumor standardized uptake value (SUVmax) measured by 18F-fluorodeoxyglucose positron emission tomography prior to chemotherapy in estrogen receptor (ER)-positive breast cancer. We hypothesized that glucose hypermetabolism by luminal B tumors may result in chemotherapy responsiveness. Using a single-gene expression assay, TargetPrint® (Agendia) and a 70-gene expression classifier,MammaPrint® (Agendia), we divided 20 patients with ERpositive primary breast cancer into luminal A and luminal B subtypes and compared the tumor SUVmax value between the two groups. A significantly higher SUVmax was measured for luminal B tumors (n=10; mean±SD, 7.6±5.6) than for luminal A tumors (n=10; mean±SD, 2.6±1.2; p=0.01). Glucose hypermetabolism could help predict intrinsic subtyping and chemotherapy responsiveness as a supplement to ER, progesterone receptor, HER2,and Ki-67 histochemical scores.
Keiichi Nakahara,Satoshi Yamashita,Katsumasa Ideo,Seigo Shindo,Tomohiro Suga,Akihiko Ueda,Shoji Honda,Tomoo Hirahara,Masaki Watanabe,Taro Yamashita,Yasushi Maeda,Yasuhiro Yonemochi,Tomohiro Takita,Yuk 대한신경과학회 2014 Journal of Clinical Neurology Vol.10 No.4
Background Listeria monocytogenes (L. monocytogenes) is a rare causative pathogen ofbrain abscess that is often found in immunocompromised patients. Although patients with supratentorial listerial abscesses showed a longer survival with surgical drainage, the standardtherapy for patients with subtentorial lesions has not been established. Case Report We report herein a patient with supra- and subtentorial brain abscesses causedby L. monocytogenes infection. These abscesses did not respond to antibiotics, and his symptoms gradually worsened. Drainage was not indicated for subtentorial lesions, and the patientwas additionally treated with hyperbaric oxygen therapy, which dramatically reduced the volume of abscesses and improved the symptoms. Conclusions This is the first report of drastic therapy for a patient with listerial brain abscesses involving combined antibiotics and hyperbaric oxygen therapy. The findings suggestthat hyperbaric oxygen therapy is a good option for treating patients with deep-seated listerialabscesses and for who surgical drainage is not indicated.